Issue 3, 2021

Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form

Abstract

Inhibition of immunomodulating enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is considered one of the potential approaches in the fight against cancer and other diseases. Comprehensive biophysical and cellular studies have shown that quinine derivatives effectively inhibit the activity of IDO1. Mechanistic studies revealed that the potent quinine derivatives compete with heme for binding to apo-IDO1 and perturb its reversible binding propensity to apo-IDO1 via the formation of a heme-inhibitor complex. This IDO1 inhibitory pathway could provide new avenues to immunotherapy-based drug discovery strategies.

Graphical abstract: Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form

Supplementary files

Article information

Article type
Communication
Submitted
19 Oct 2020
Accepted
30 Nov 2020
First published
08 Dec 2020

Chem. Commun., 2021,57, 395-398

Inhibition of immunosuppressive indoleamine 2,3-dioxygenase by targeting the heme and apo-form

N. Pradhan, N. Akhtar, B. Nath, J. Peña-García, A. Gupta, H. Pérez-Sánchez, S. Kumar and D. Manna, Chem. Commun., 2021, 57, 395 DOI: 10.1039/D0CC06942F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements